New drug shows promise for Tough-to-Treat prostate cancer

NCT ID NCT04702737

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested a drug called Tarlatamab in 41 men with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer. The main goal was to check the drug's safety and find the best dose. The drug works by helping the body's immune cells recognize and attack cancer cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tarlatamab (also called AMG 757), a drug that helps immune cells attack cancer cells
What this could lead to: If successful, this could lead to a new treatment option for men with a rare and aggressive form of prostate cancer that currently has few options.
What could go wrong: This is an early phase 1 trial with only 41 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE PROSTATE CANCER

Contacts and locations

Locations

Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia
Community Health Network MD Anderson Cancer Center - North

Indianapolis, Indiana, 46250, United States
Erasmus Medisch Centrum

Rotterdam, 3015 GD, Netherlands
Gustave Roussy

Villejuif, 94805, France
Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, 08036, Spain
Keio University Hospital

Shinjuku-ku, Tokyo, 160-8582, Japan
Landeskrankenhaus Salzburg

Salzburg, 5020, Austria
Mayo Clinic Arizona

Phoenix, Arizona, 85054, United States
Medizinische Universitaet Graz

Graz, 8036, Austria
Ordensklinikum Linz Elisabethinen

Linz, 4020, Austria
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Royal Marsden Hospital

Sutton, SM2 5PT, United Kingdom
The Ohio State University

Columbus, Ohio, 43210, United States
Universitair Ziekenhuis Gent

Ghent, 9000, Belgium
University of California at San Francisco Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94158, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27103, United States
Washington University

St Louis, Missouri, 63110-1093, United States
Weill Cornell Medical College

New York, New York, 10021, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.